Levamlodipine (S-amlodipine), the pharmacologically active enantiomer of amlodipine, is a highly potent oral L-type calcium channel blocker and MMP-9 inhibitor. It is widely used as a first-line antihypertensive and antianginal agent in cardiovascular therapy. By selectively blocking calcium influx into vascular smooth muscle and myocardial cells, it relaxes blood vessels, reduces peripheral resistance, and lowers blood pressure with minimal reflex tachycardia. It also stabilizes atherosclerotic plaques by inhibiting MMP-9 expression, improving lipid profiles, and reducing vascular inflammation. Clinically, it treats essential hypertension, chronic stable angina, and vasospastic angina, with higher efficacy and fewer side effects than racemic amlodipine. It is also used in pharmaceutical research for hypertension, atherosclerosis, and heart failure studies, and as a reference standard for chiral drug development and quality control.
GHS classification: Warning (H302, H315, H319, H335). Acute oral LD50 (rat) >2000 mg/kg (low toxicity). Skin contact may cause mild irritation, redness, or dryness; prolonged/repeated exposure may cause dermatitis. Eye contact leads to stinging, tearing, and conjunctivitis. Inhalation of dust irritates the respiratory tract, causing cough or throat discomfort. No evidence of carcinogenicity, mutagenicity, or reproductive toxicity under normal use. Avoid ingestion, inhalation, and skin/eye contact. Handle in a ventilated fume hood with nitrile gloves, safety goggles, and dust masks. Skin contact: wash with soap and water. Eye contact: rinse with water for ≥15 minutes. Store sealed in a cool, dry place (2–8 °C), away from oxidants, acids, and food. Dispose per local hazardous waste regulations.
